Bristol-Myers Squibb Company (ETR:BRM)
Germany · Delayed Price · Currency is EUR | Market Cap | 82.08B |
| Revenue (ttm) | 40.94B |
| Net Income (ttm) | 5.15B |
| Shares Out | n/a |
| EPS (ttm) | 2.53 |
| PE Ratio | 15.95 |
| Forward PE | 7.31 |
| Dividend | 2.22 (5.49%) |
| Ex-Dividend Date | Oct 3, 2025 |
| Volume | 1,727 |
| Average Volume | 4,549 |
| Open | 40.44 |
| Previous Close | 40.16 |
| Day's Range | 40.21 - 40.45 |
| 52-Week Range | 36.60 - 58.79 |
| Beta | 0.31 |
| RSI | 61.72 |
| Earnings Date | Oct 30, 2025 |
About ETR:BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthrit... [Read more]
News
JPMorgan Chase & Co. Acquires Significant Stake in Bristol-Myers Squibb Co.
JPMorgan Chase & Co. Acquires Significant Stake in Bristol-Myers Squibb Co.
Bristol Myers (BMY) Agrees to $239 Million Settlement Over Celgene Claims
Bristol Myers (BMY) Agrees to $239 Million Settlement Over Celgene Claims
Bristol-Myers Squibb: Way Too Cheap At 7x P/E
Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership
BioNTech SE (NASDAQ: BNTX) reported a third-quarter per-share loss of 14 cents (12 cents in euros) on Monday, a turnaround from earnings of 81 cents reported a year ago, missing the consensus earning...
Bristol-Myers Squibb (BMY) Announces $7 Billion Cash Tender Offers
Bristol-Myers Squibb (BMY) Announces $7 Billion Cash Tender Offers
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data from its cardiovascular portfolio at the American Heart Association’s Scientific Sessions 2025, taking place November 7–10, 20...
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes
Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb” or the “Offeror”), announced the commencement of tender offers (“Offers”) to purchase for cash certain of its outstanding notes (collec...
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
Final Trades: Rocket Companies, Meta, Cleveland-Cliffs, Bristol Myers
The Investment Committee give you their top stocks to watch for the second half.
Bristol-Myers Squibb (BMY) Raises 2025 Revenue Guidance Amid Strong Q3 Performance
Bristol-Myers Squibb (BMY) Raises 2025 Revenue Guidance Amid Strong Q3 Performance
Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic ...
Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic Advancements
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDTCompany ParticipantsChuck TrianoChristopher Boerner - CEO &...
Bristol Myers' New Treatments Drive Q3 Beat — And The Company's Raising Its Outlook
Bristol Myers beats Q3 forecasts with $12.22 billion ... Full story available on Benzinga.com
Bristol Myers (BMY) Withdraws from Metsera Acquisition Bidding
Bristol Myers (BMY) Withdraws from Metsera Acquisition Bidding
Bristol Myers Squibb (BMY) Boosts 2025 Outlook Following Strong Q3
Bristol Myers Squibb (BMY) Boosts 2025 Outlook Following Strong Q3
Q3 2025 Bristol-Myers Squibb Co Earnings Call Transcript
Q3 2025 Bristol-Myers Squibb Co Earnings Call Transcript
Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead
Bristol-Myers Squibb Company remains a solid, cash-generative blue-chip stock, with expected slow growth & patience. Learn more about BMY stock here.
Here's why Bristol Myers quarter wasn't enough to change our view on the stock
The company's future hinges on the success of Cobenfy, the company's new schizophrenia drug.
December 12th Options Now Available For Bristol Myers Squibb (BMY)
Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the December 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the B...
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
Bristol-Myers Squibb (BMY) Exceeds Q3 Earnings Expectations
Bristol-Myers Squibb (BMY) Exceeds Q3 Earnings Expectations
Bristol-Myers Squibb (BMY) Updates Revenue Projections for Fiscal Year 2025
Bristol-Myers Squibb (BMY) Updates Revenue Projections for Fiscal Year 2025
Bristol-Myers Squibb Company 2025 Q3 - Results - Earnings Call Presentation
Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates
Bristol Myers (BMY) delivered earnings and revenue surprises of +10.14% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?